Cerus Co. (CERS) Given Average Recommendation of “Hold” by Analysts

Shares of Cerus Co. (NASDAQ:CERS) have been assigned an average recommendation of “Hold” from the eight research firms that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $6.50.

CERS has been the topic of several research reports. Zacks Investment Research upgraded Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, November 8th. Cantor Fitzgerald restated an “overweight” rating and set a $5.00 price objective on shares of Cerus in a research note on Friday, January 5th. BidaskClub upgraded Cerus from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. BTIG Research restated a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. Finally, ValuEngine upgraded Cerus from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th.

Cerus (NASDAQ CERS) traded down $0.08 during trading hours on Tuesday, hitting $3.85. The company had a trading volume of 744,600 shares, compared to its average volume of 1,906,219. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71. Cerus has a fifty-two week low of $1.93 and a fifty-two week high of $5.43. The firm has a market capitalization of $488.95, a PE ratio of -6.53 and a beta of 2.22.

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of Cerus by 1.8% during the fourth quarter. BlackRock Inc. now owns 8,485,711 shares of the biotechnology company’s stock valued at $28,682,000 after purchasing an additional 150,587 shares during the last quarter. Elk Creek Partners LLC grew its holdings in shares of Cerus by 6.8% during the third quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock valued at $16,730,000 after purchasing an additional 388,741 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Cerus by 3.9% during the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after purchasing an additional 184,076 shares during the last quarter. ARK Investment Management LLC grew its holdings in shares of Cerus by 32.8% during the fourth quarter. ARK Investment Management LLC now owns 3,564,373 shares of the biotechnology company’s stock valued at $12,048,000 after purchasing an additional 881,171 shares during the last quarter. Finally, Senvest Management LLC grew its holdings in shares of Cerus by 7.0% during the fourth quarter. Senvest Management LLC now owns 3,166,398 shares of the biotechnology company’s stock valued at $10,702,000 after purchasing an additional 206,000 shares during the last quarter. Hedge funds and other institutional investors own 51.52% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cerus Co. (CERS) Given Average Recommendation of “Hold” by Analysts” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/13/cerus-co-cers-given-average-recommendation-of-hold-by-analysts.html.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply